A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients
Recruiting · NCT06493760 · Interventional (participants receive a specific treatment) · Lead sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This study includes two parts:Part 1: SSGJ-707 (different dosing regimens) in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.Part 2: SSGJ-707 in combination with chemotherapy versus bevacizumab in combination with chemotherapy for first-line treatment of metastatic colorectal cancer.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Males and/or females over age 18
- Histologically and/or cytologically documented metastatic colorectal cancer confirmed .
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Expected survival \>=12 weeks.
- Signed informed consent form.
Exclusion criteria
- Known uncontrolled or symptomatic central nervous system metastatic disease.
- Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0).
- Inadequate organ or bone marrow function.
- Pregnant or breast-feeding woman.
- Known allergies, hypersensitivity, or intolerance to SSGJ-707 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Where it is running
1 location listed.
- Liu Tianshu - Shanghai, Shanghai Municipality, China